Amneal Pharmaceuticals Inc (AMRX)

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire...

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically...

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring...

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Amneal Reports First Quarter 2026 Financial Results

‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒‒...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors